pasotuxizumab
pasotuxizumab noun: a bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer.
Noun
pasotuxizumab (uncountable)
- A bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer.
- Pasotuxizumab (AMG 212) is a canonical BiTE antibody targeting PSMA [77]. The anti-tumor activity which was defined by PSA level decrease was dose-dependent. Two patients achieved long-term PSA responses with more than 1 year of treatment at doses of 40 μg/d and 80 μg/d, respectively.2021 May 26, Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu, “The landscape of bispecific T cell engager in cancer treatment”, in Biomarker Research, volume 9, →DOI, article 38, page 4
Origin of pasotuxizumab
From [Term?] + -tu- (“tumor”) + -xi- (“chimeric”) + -zumab (“humanized monoclonal antibody”).
Questions about pasotuxizumab
- What does pasotuxizumab mean?
- Pasotuxizumab means a bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer.
- What part of speech is pasotuxizumab?
- Pasotuxizumab is a noun.
Words near pasotuxizumab in the dictionary
Source and license
Adapted from Wiktionary: pasotuxizumab (page history and authors). Text available under the Creative Commons Attribution-ShareAlike 4.0 license. Word.ws reformatted the entry and added links. Wiktionary data of 2026-09-02.
Last updated:
Cite this entry: “pasotuxizumab.” Word.ws, https://word.ws/pasotuxizumab. Based on Wiktionary, CC BY-SA 4.0.
